ERBB2 and non-small cell lung carcinoma: The 4B5 clone had a positive likelihood ratio excluding unity but did not possess negative discriminatory capability within a 95% CI This study suggests that, for the detection of HER2 amplification (confirmed by either FISH or NGS), two commercially available clones may have sufficient sensitivity and specificity to warrant consideration as a screening test for HER2-amplified NSCLC, should such a treatment be found effective in NSCLC.